TNSN08266A1 - Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit - Google Patents
Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unitInfo
- Publication number
- TNSN08266A1 TNSN08266A1 TNP2008000266A TNSN08266A TNSN08266A1 TN SN08266 A1 TNSN08266 A1 TN SN08266A1 TN P2008000266 A TNP2008000266 A TN P2008000266A TN SN08266 A TNSN08266 A TN SN08266A TN SN08266 A1 TNSN08266 A1 TN SN08266A1
- Authority
- TN
- Tunisia
- Prior art keywords
- reverse transcriptase
- nucleotide
- tenofovir
- lamivudine
- nucleoside reverse
- Prior art date
Links
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 title abstract 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 title abstract 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 title 1
- 229960001627 lamivudine Drugs 0.000 title 1
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 229960004556 tenofovir Drugs 0.000 title 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229940123527 Nucleotide reverse transcriptase inhibitor Drugs 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A pharmaceutical formulation for the treatment of HIV is provided. The formulation is a combination of a nucleoside reverse transcriptase inhibitor and a nucleotide reverse transcriptase inhibitor in which the combination has an increased stability over prior, art combination therapies. The invention also provides a pharmaceutical product containing the formulation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1566MU2005 | 2005-12-14 | ||
| PCT/GB2006/004687 WO2007068934A2 (en) | 2005-12-14 | 2006-12-14 | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN08266A1 true TNSN08266A1 (en) | 2009-10-30 |
Family
ID=41022655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2008000266A TNSN08266A1 (en) | 2005-12-14 | 2008-06-16 | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
Country Status (3)
| Country | Link |
|---|---|
| ES (1) | ES2349479T3 (en) |
| TN (1) | TNSN08266A1 (en) |
| ZA (1) | ZA200805254B (en) |
-
2006
- 2006-12-14 ES ES06820527T patent/ES2349479T3/en active Active
-
2008
- 2008-06-16 TN TNP2008000266A patent/TNSN08266A1/en unknown
- 2008-06-17 ZA ZA200805254A patent/ZA200805254B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2349479T3 (en) | 2011-01-04 |
| ZA200805254B (en) | 2009-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007068934A3 (en) | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit | |
| NO20071077L (en) | Phosphonate analogues for HIV inhibitor compounds | |
| IL181987A0 (en) | Diaminotriazole derivatives and pharmaceutical compositions containing the same | |
| ATE493413T1 (en) | ANHYDROUS CRYSTALLINE FORMS OF N-Ä1,2- ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINOÜ-7-(4- METHYLPYRIDINE-2-YL-AMINOÜ-1H-PYRAZOLOÄ4,3- | |
| MXPA05008368A (en) | Hiv inhibiting 1,2,4-triazines. | |
| NO20081592L (en) | Dipeptidyl peptidase inhibitors for the treatment of diabetes | |
| IL184898A0 (en) | Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same | |
| IS7817A (en) | Phenylalanine derivatives which dipeptidyl peptidase inhibit the treatment or prevention of diabetes. | |
| UA100005C2 (en) | Inhibitors of human immunodeficiency virus replication | |
| GEP20125691B (en) | Compounds and compositions as protein kinase inhibitors | |
| EP2526934A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| DE602005014382D1 (en) | 2-pyrimidinyl pyrazolopyridine ERBB Kinase Inhibitors | |
| WO2008028965A3 (en) | Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof | |
| MY140514A (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
| WO2007113243A3 (en) | Use of pde 5 inhibitors for the treatment of overactive bladder | |
| TN2009000119A1 (en) | Combination drug | |
| IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
| IL191670A0 (en) | Compounds for the inhibition of apoptosis | |
| TNSN08266A1 (en) | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit | |
| TW200621261A (en) | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof | |
| MY140530A (en) | Antineoplasic compounds and pharmaceuticals compositions thereof | |
| UA93689C2 (en) | Administration of dipeptidyl peptidase inhibitors | |
| TW200500338A (en) | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |